Drug Trial Radar · NCT03182244
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Oct 25, 2017
Primary completion
Dec 25, 2023
Study completion Jul 29, 2026
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were refractory to or had relapse after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study evaluated safety as well as determined the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.
Conditions
- AML With FLT3 Mutation
Interventions
GilteritinibDrug
Tablet administered orally once daily.
CytarabineDrug
Once/twice daily Intravenously (IV)/subcutaneously (SC).
MitoxantroneDrug
Once daily IV injection.
EtoposideDrug
Once daily IV injection.
G-CSFDrug
Once daily IV/SC injection.
FludarabineDrug
Once daily IV injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From the date of randomization up to the date of death (up to approximatley 74 months)
Locations
49 sites in 5 countries. Site status is shown where the registry gives one.
Site CN103
Beijing, China
Site CN108
Beijing, China
Site CN109
Beijing, China
Site CN110
Beijing, China
Site CN131
Beijing, China
Site CN116
Changchun, China
Site CN120
Changsha, China
Site CN119
Fuzhou, China
Site CN102
Guangzhou, China
Site CN114
Guangzhou, China
Site CN121
Guangzhou, China
Site CN130
Guiyang, China
Site CN107
Hangzhou, China
Site CN118
Hefei, China
Site CN123
Huangpu Qu, China
Site CN117
Jinan, China
Site CN133
Lanzhou, China
Site CN128
Nanjing, China
Site CN106
Qingdao, China
Site CN126
Shanghai, China
Site CN129
Shanghai, China
Site CN125
Shenyang, China
Site CN101
Tianjin, China
Site CN105
Wuhan, China
Site CN122
Xi'an, China
Site CN132
Zhangzhou, China
Site CN113
Zhengzhou, China
Site CN136
Zhengzhou, China
Site MY306
Ampang, Malaysia
Site MY305
George Town, Malaysia
Site MY301
Johor Bahru, Malaysia
Site MY304
Kota Kinabalu, Malaysia
Site MY302
Kuala Lumpur, Malaysia
Site MY303
Pulau Pinang, Malaysia
Site RU506
Kemerovo, Russia
Site RU504
Krasnoyarsk, Russia
Site RU508
Moscow, Russia
Site RU509
Moscow, Russia
Site RU501
Saint Petersburg, Russia
Site RU502
Saint Petersburg, Russia
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.